BioPharma APAC - Leading Source of Biopharmaceutical Intelligence in Asia Pacific

Contract Services

Piramal Pharma Acquires Majority Stake in Yapan Bio to Strengthen Biologics CDMO Capabilities

Yapan Bio Private Limited specializes in process development, characterization, and phase I and II GMP manufacturing services for vaccines and biologics....

August 19, 2026 | News

Merck Expands Singapore BioReliance Lab with First Cell Line Characterisation and GMP NGS Capabilities in Asia Pacific

Expansion adds first BioReliance® Cell Line Characterization and GMP Next-Generation Sequencing in Asia Pacific Enhanced testing capabilities t...

August 12, 2026 | News

Porton Advanced Secures China Commercial Manufacturing Licence for Cell and Gene Therapy CDMO Services

Porton Advanced Solutions Ltd. ("Porton Advanced") has officially been granted a Drug Manufacturing License (Class C) by the National Medical Products Admi...

August 07, 2026 | News

Enzene Launches NeX™ to Enable Local Biologics Manufacturing Worldwide

Enzene, a leading global continuously innovative development and manufacturing organization (CIDMO™), announced the launch of NeX™, a transform...

August 05, 2026 | News

The APAC CDMO Shortlist: 10 CDMOs to Watch Through 2028

There is a version of this list that writes itself. Rank the region’s contract manufacturers by installed litres, put Samsung Biologics at the top, a...

July 24, 2026 | Analysis

Samsung Bioepis Secures Exclusive Commercial Rights to Nectin-4 ADC Candidate SBE303

Ÿ Under the agreement, Samsung Bioepis will obtain exclusive commercial licensing rights to SBE303, an ADC candidate currently in joi...

July 24, 2026 | News

Lonza and Engitix Partner to Advance Next-Generation ECM-Targeted ADCs

Lonza grants Engitix target-specific license for GlycoConnect®, HydraSpace® and SYNtecan E™ linker-payload technologies for ADC de...

July 22, 2026 | News

Samsung Biologics Launches CHF 1.46B All-Cash Bid to Acquire PolyPeptide

Samsung Biologics to launch an all-cash public tender offer for 100% of PolyPeptide's fully diluted share capital (excluding therefrom any treasury share...

July 21, 2026 | News

Merck Invests €25M to Expand BioReliance Testing Capabilities in Europe

• New 2,000-square-meter facility expands Merck’s global testing network with commercial drug substance and drug product release testing a...

July 17, 2026 | News

China Plus One: Slogan, Strategy, or Capacity APAC Does Not Have?

THE RESHUFFLE · ANALYSIS On a Monday in June 2026, one line in the United States Federal Register did what two year...

July 16, 2026 | Analysis

Can APAC Biomanufacturing Decarbonise Without Pricing Itself Out?

Scope 3 clauses, single-use plastic, water and energy intensity: the “green premium” has become the defining question for the CDMOs that built ...

July 14, 2026 | Analysis

Matica Bio Partners with VaxDome to Advance Novel Intranasal Antiviral Vaccine Platform into Clinical Trials

Matica Biotechnology, Inc. ("Matica Bio"), a viral vector contract development and manufacturing organization (CDMO), is partnering with Texas-based biotec...

July 08, 2026 | News

The Biosimilar Race: Factory to the World — or Stuck in the Copycat Economy?

In Songdo and Bengaluru, the numbers finally look like the ones the region was promised a decade ago. Celltrion closed 2025 with revenue above ₩4 trillio...

July 07, 2026 | Analysis

Samsung Biologics Accelerates Sustainability Strategy with Stronger ESG Performance

Advanced environmental performance through renewable energy transition and enhanced carbon transparency Strengthened sustainability management and suppl...

July 02, 2026 | News

Stay Connected